Instructions for CME/CE Participants

American Cancer Society. Cancer Facts & Figures 2016. http://www.cancer.org/acs/groups/content/@research/documents/document/ac-spc-047079.pdf. Accessed September 26, 2016.

Reck M. , von Pawel J. , Zatloukal P. Overall survival with cisplatingemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small cell lung cancer: results from a randomised phase III trial. Ann Oncol. 2010; 21(9): 1804–1809.

Ciuleanu T. , Brodowicz T. , Zielinski C. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind phase 3 study. Lancet. 2009; 374(9699): 1432–1440.

Fidias P.M. , Dakhil S.R. , Lyss A.P. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol. 2009; 27(4): 591–598.

Brodowicz T. , Krzakowski M. , Zwitter M. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006; 52(2): 155–163.

Leighl N.B. , Paz-Ares L. , Douillard J.Y. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol. 2005; 23(12): 2831–2839.

Williamson S.K. , Crowley J.J. , Lara P.N. Jr . Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005; 23(36): 9097–9104.